Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848602 | 1.00 | MAPK14 (0.39) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4853763 | 0.91 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4853753 | 0.91 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4875101 | 0.89 | MAPK14 (0.40) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4875118 | 0.89 | MAPK14 (0.40) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4857822 | 0.88 | MAPK14 (0.35) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4857829 | 0.88 | MAPK14 (0.35) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4859032 | 0.85 | MAPK14 (0.35) | MAPK14MAPK11MAPK13MAPK12MAPK8 | |
| SCHEMBL4848848 | 0.85 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL4848856 | 0.85 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | claimed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | DPYD, IL1B, IL6 | MAPK14 2806/4885MAPK11 3788/4885MAPK13 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.